Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Advanced Alveolar Soft Part Sarcoma Clear all
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
42
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 8:08 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
Interventions
Selinexor, Ixazomib
Drug
Lead sponsor
Matthew Ingham
Other
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
AZD2171
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 16 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced May 21, 2026, 8:08 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Refractory Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Selinexor
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Hartford, Connecticut • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
Interventions
FAZ053, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's, Sarcoma, Alveolar Soft Part, Chordoma, Epithelioid Sarcoma, Giant Cell Tumor of Bone, Hemangiopericytoma, Gastrointestinal Stromal Tumor (GIST)
Interventions
Dasatinib
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
13 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
20
States / cities
Little Rock, Arkansas • Duarte, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced May 21, 2026, 8:08 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions
AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Park Ridge, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced May 21, 2026, 8:08 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Melanoma, Metastatic Melanoma
Interventions
Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 8:08 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
Interventions
Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas
Interventions
Axitinib, Pembrolizumab
Drug
Lead sponsor
Jonathan Trent, MD, PhD
Other
Eligibility
16 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced May 21, 2026, 8:08 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Endometrial Cancer, Ovarian Cancer, Sarcoma
Interventions
temozolomide
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone
Interventions
Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Vismodegib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced May 21, 2026, 8:08 PM EDT